Summary

Market Overview
The global osteoporosis testing market reached US$ 383.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 566.8 million by 2030. The global osteoporosis testing market is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030). The growing adoption of X-rays and the rise in the various end-use applications of X-rays are expected to drive demand for diagnostic imaging services in the osteoporosis testing market during the forecast period.
For instance, in 2020, RadNet and Dignity Health launched a collaborative venture in Arizona. This venture aided in Dignity Health and RadNet’s current commitment to provide patients and targeted medical communities. For instance, Philips N.V. launched a newer version of CT in 2021 called Spectral CT 7500, which is primarily used for precision diagnosis.
The factors influencing the global osteoporosis testing market are technological advancements and the increasing prevalence of osteoporosis. Osteoporosis is a disease that can worsen over time. This can cause the bone to become more porous and prone to breaking. Dual Energy X-ray Absorptiometry, also known as a DXA or DEXA scan, is the current gold-standard method for diagnosing osteoporosis.
However, the high cost of the product is expected to hamper the market growth. For instance, the cost of the DXA instrument, which is likely to exceed US$ 100,000, accounts for the majority of the costs associated with its use. However, DXA is better suited to lab-based research rather than field testing.
Market Dynamics
The technological advancements lead to the market’s growth and is one of the main factors driving the market growth.
A variety of technologies have been used to assess skeletal health, the most common of which is dual-energy X-ray absorptiometry (DXA), which measures the spine, hip, or entire body. The skeletal health assessment has become faster and more accurate due to recent advances in imaging technology.
For instance, the Hologic, Bedford, MA-based Discovery QDR Series bone densitometer includes High-Definition Instant Vertebral Assessment (IVA), which takes a 10-second scan of the lumbar, thoracic spine to detect vertebral deformities. This allows classifying more patients as osteoporotic, even if their BMD results are borderline.
The physician can use this to take quick images and determine whether there is a vertebral compression fracture. These advancements aim to improve the DXA basic bone density system's utility in assessing overall patient health and are expected to drive osteoporosis testing market growth over the forecast period.
Limitations associated with osteoporosis testing are factors hindering the market growth.
A DXA test cannot predict who will fracture. DXA is of limited use in people with a spinal deformity or those who have had previous spinal surgery, despite its effectiveness in measuring bone density.
Accurate measurement of these skeletal parameters through the development of better imaging scanners is critical to advancing fracture risk assessment and informing clinicians on the best treatment strategy.
Moreover, all the X-ray-based methods provide a measure of BMD but this parameter can explain only 60%-80% of the variability in bone strength, and it has demonstrated other mechanical aspects of the bone (microarchitectural parameters, bone geometry, and elastic properties), which cannot be assessed by densitometric techniques. Thus, these factors will hamper the market growth over the forecast period.
COVID-19 Impact Analysis
During the COVID-19 pandemic, screening, diagnosis, and treatment of patients with osteoporosis proved difficult. Patients' access to metabolic bone clinics has been disrupted, causing future problems due to treatment delays, particularly in denosumab patients.
During the pandemic, the quality of osteoporosis care for patients who suffered a new fragility fracture or hip fracture following surgery deteriorated drastically. Hence, the global osteoporosis testing market was negatively impacted by COVID-19.
Several medical societies provided recommendations to promote patient and staff safety during the pandemic, including the International Society for Clinical Densitometry (ISCD), which recognized that bone densitometry testing with dual-energy x-ray absorptiometry (DXA) has been affected and idled by the crisis.
Russia-Ukraine Conflict Analysis
The conflict between Russia and Ukraine has caused a disruption of the supply chain for some of the equipment used in osteoporosis testing, increasing costs for consumers and making it more difficult for them to access the necessary testing. These factors have had a significant impact on the osteoporosis testing market.
Segment Analysis
The global osteoporosis testing market is segmented based on type, end user and region.
The X-ray scan segment will be dominated by market players during the forecast period.
The X-ray scan segment accounted for the highest market share accounting for approximately 59.7% of the osteoporosis testing market in 2022. X-ray is very helpful and crucial in the diagnosis of osteoporosis. The key X-ray finding indicative of osteoporosis is the loss of bone mass. The main loss is found in the bony trabecula rather than the cortex. The results of a bone density scan are generally utilized alongside a fracture risk assessment to evaluate the chances of breaking a bone or osteoporosis.
Anyone can get affected by osteoporosis at any age, although post-menopausal older women are at high risk. This is due to the decline of estrogen levels after menopause, which results in low bone density. The more dense the bones are, the less likely and stronger they are to get fractured or broken. Osteoporosis may not show any symptoms until a fracture of the bone.
Geographical Analysis
North America holds a dominant position in the market.
North America held 38.5% osteoporosis testing market share in 2022. The most prevalent bone disease, osteoporosis, which affects roughly 10 million people in the U.S. alone, causes bones to become weak and prone to fractures. According to AMGA Foundation, nearly 54 million Americans have osteoporosis or low bone density, and approximately one in two women and one in four men aged 50 and older will break a bone due to osteoporosis. Fractures often have a devastating effect on patients and lead to billions in direct care costs each year.
Many people with osteoporosis do not know they have the disease until after a broken bone. Unfortunately, recent evidence shows that even after a fracture, less than 15 percent of commercially insured US patients receive treatment for osteoporosis.
Competitive Landscape
The major global players include GE Healthcare, DMS Imaging, Swissray, BeamMed, Hologic, OSTEOSYS, Scanflex Healthcare, CompuMed, FUJIFILM, and Trivitron Healthcare among others.
Why Purchase the Report?
• To visualize the global osteoporosis testing market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global osteoporosis testing market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global osteoporosis testing market report would provide approximately 92 tables, 108 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents